Long-Term PEG-J Tube Safety in Patients With Advanced Parkinson's Disease.

ABSTRACT:

Objectives

The objectives of this study were to present procedure- and device-associated adverse events (AEs) identified with long-term drug delivery via percutaneous endoscopic gastrojejunostomy (PEG-J). Levodopa-carbidopa intestinal gel (LCIG, also known in US as carbidopa-levodopa enteral suspension, CLES) is continuously infused directly to the proximal small intestine via PEG-J in patients with advanced Parkinson's disease (PD) to overcome slow and erratic gastric emptying and treat motor fluctuations that are not adequately controlled by oral or other pharmacological therapy.

Methods

An independent adjudication committee of three experienced (>25 years each) gastroenterologists reviewed gastrointestinal procedure- and device-associated AEs reported for PD patients (tot

SUBMITTER: Epstein M 

PROVIDER: S-EPMC4822096 | biostudies-literature | 2016 Mar

REPOSITORIES: biostudies-literature